The C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis drives immune exclusion in pancreatic ductal adenocarcinoma (PDA). Building on our preclinical data, we conducted the first stage of an open-label, single-arm phase 2 clinical trial combining CXCR4 inhibition (motixafortide), PD-...
A. Raufi, Edridge K. D'Souza, Michael S. May et al.· Nature Communications· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to immunotherapy because of its immunosuppressive, T-cell–excluded microenvironment. Immune checkpoint blockade, alone or with chemotherapy, has shown limited efficacy, likely due to redundant suppressive pathways. CAF-derived CXCL12 acting throug...
I. Pellicciotta, G. Manji, A. Raufi et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) continues to carry a poor prognosis, and only incremental gains in systemic therapy have been made over the past decade. Because activating KRAS mutations are present in more than 90% of PDAC and serve as the inciting oncogenic driver, RAS has long been a coveted but elusive ther...
Y. L. Wu, B. Herzberg, G. Manji· The Oncologist· 0 citations
The authors apply ARACNe and metaVIPER to published scRNA-seq datasets to characterize pancreatic cancer subtypes, identifying six distinct cell states as well as their mechanistic determinants.
P. Laise, Mikko M. Turunen, Álvaro Curiel-García et al.· Nature Genetics· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
